Reuters
17 Jul 2026, 08:39 UTC · 1h ago
India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
17 Jul 2026, 08:39 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
India's drug regulator has approved Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). — Approval for a new indication (MASH) in a massive market like India significantly expands the addressable patient population and revenue potential for Wegovy.
+0.60Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Search tags
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
5h ago
